tirzepatide litigation Eli Lilly can proceed with lawsuit against telehealth seller of weight-loss drugs According to a criminal complaint,

Reiss AB et al

As of 2024, compounded semaglutide from licensed pharmacies remains a standard treatment pathway recommended by endocrinologists and obesity medicine specialists across the country

In 2021, the FDA issued guidance expecting generic peptide drugs to be produced chemically 3 , signaling that chemical synthesis could be the regulatory default for this drug class

GLP-1 receptor activation reduces appetite, slows gastric emptying, promotes insulin secretion from pancreatic beta cells, and creates the characteristic feeling of fullness that GLP-1 agonist users report

The compounded GLP-1 wrinkle Many telehealth providers offered compounded semaglutide and tirzepatide during the drug shortages